Analysis of vitamin D metabolites by liquid chromatography-tandem mass spectrometry

TrAC - Trends in Analytical Chemistry

Volumn 84, Issue , 2016, Pages 117-130

  van den Ouweland, Johannes M W ^a  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

1,25 dihydroxyvitamin D; 24,25 dihydroxyvitamin D; 25 hydroxyvitamin D; 3 epi 25 hydroxyvitamin D; Liquid chromatography; Mass spectrometry; Metabolite profiling; Vitamin D

Indexed keywords

BIOMOLECULES; CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES; SPECTROMETRY; VITAMINS;

25-HYDROXYVITAMIN D; 3-EPI-25-HYDROXYVITAMIN D; CALCIUM HOMEOSTASIS; COMBINED MEASUREMENTS; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; METABOLITE PROFILING; SIMULTANEOUS DETERMINATIONS; VITAMIN-D;

LIQUID CHROMATOGRAPHY;

24,25 DIHYDROXYVITAMIN D; 25 HYDROXYVITAMIN D; 3 EPI 25 HYDROXYVITAMIN D; CALCITRIOL; COLECALCIFEROL DERIVATIVE; UNCLASSIFIED DRUG;

HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; METABOLITE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; TANDEM MASS SPECTROMETRY; VITAMIN METABOLISM;

EID: 84959529155     PISSN: 01659936     EISSN: 18793142     Source Type: Journal    
DOI: 10.1016/j.trac.2016.02.005     Document Type: Review

References (186)

1. [1] Elder, C.J., Bishop, N.J., Rickets. Lancet 383 (2014), 1665–1676.
2. [2] Christodoulou, S., Goula, T., Ververidis, A., Drosos, G., Vitamin D and bone disease. Biomed Res. Int, 2013, 2013, 396541.
3. [3] Holick, M.F., Vitamin D deficiency. N. Engl. J. Med 357 (2007), 266–281.
4. [4] Plum, L.A., DeLuca, H.F., Vitamin D, disease and therapeutic opportunities. Nat. Rev. Drug Discov 9 (2010), 941–955.
5. [5] Reid, I.R., What diseases are causally linked to vitamin D deficiency?. Arch. Dis. Child 101 (2016), 185–189.
6. [6] Sattar, N., Welsh, P., Panarelli, M., Forouhi, N.G., Increasing requests for vitamin D measurement: costly, confusing, and without credibility. Lancet 379 (2012), 95–96.
7. [7] Ross, A.C., Manson, J.E., Abrams, S.A., Aloia, J.F., Brannon, P.M., Clinton, S.K., et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab 96 (2011), 53–58.
8. [8] Holick, M.F., Binkley, N.C., Bischoff-Ferrari, H.A., Gordon, C.M., Hanley, D.A., Heaney, R.P., et al. Endocrine Society, Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab 96 (2011), 1911–1930.
9. [9] Holick, M.F., Binkley, N.C., Bischoff-Ferrari, H.A., Gordon, C.M., Hanley, D.A., Heaney, R.P., et al. Guidelines for preventing and treating vitamin D deficiency and insufficiency revisited. J. Clin. Endocrinol. Metab 97 (2012), 1153–1158.
10. [10] Bischoff-Ferrari, H.A., Willett, W.C., Orav, E.J., Lips, P., Meunier, P.J., Lyons, R.A., et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N. Engl. J. Med 367 (2012), 40–49.
11. [11] The DIPART (vitamin D Individual Patient Analysis of Randomized Trials) Group. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ, 340, 2010, b5463.
12. [12] Theodoratou, E., Tzoulaki, I., Zgaga, L., Ioannidis, J.P., Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ, 348, 2014, g2035.
13. [13] Chowdhury, R., Kunutsor, S., Vitezova, A., Oliver-Williams, C., Chowdhury, S., Kiefte-de-Jong, J.C., et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ, 348, 2014, g1903.
14. [14] Vieth, R., Vitamin D supplementation, 25-hydroxyvitamin D concentrations and safety. Am. J. Clin. Nutr 69 (1999), 842–856.
15. [15] Vieth, R., Vitamin D toxicity, policy, and science. J. Bone Miner. Res 22 (2007), V64–V68.
16. [16] Heaney, R.P., Armas, L.A., Quantifying the vitamin D economy. Nutr. Rev 73 (2015), 51–67.
17. [17] Durup, D., Jørgensen, H.L., Christensen, J., Schwarz, P., Heegaard, A.M., Lind, B., A reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: the CopD study. J. Clin. Endocrinol. Metab 97 (2012), 2644–2652.
18. [18] Sanders, K.M., Stuart, A.L., Williamson, E.J., Simpson, J.A., Kotowicz, M.A., Young, D., et al. Annual high-dose oral vitamin D and falls and fractures in older women. A randomized controlled trial. JAMA 303 (2010), 815–822.
19. [19] Chun, R.F., Peercy, B.E., Orwoll, E.S., Nielson, C.M., Adams, J.S., Hewison, M., Vitamin D and DBP: the free hormone hypothesis revisited. J. Steroid Biochem. Mol. Biol 144 (2014), 132–137.
20. [20] Aloia, J.F., African Americans, 25-hydroxyvitamin D, and osteoporosis: a paradox. Am. J. Clin. Nutr 88 (2008), 545S–550S.
21. [21] Powe, C.E., Evans, M.K., Wenger, J., Zonderman, A.B., Berg, A.H., Nalls, M., et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N. Engl. J. Med 369 (2013), 1991–2000.
22. [22] Aloia, J., Mikhail, M., Dhaliwal, R., Shieh, A., Usera, G., Stolberg, A., et al. Free 25(OH)D and the Vitamin D Paradox in African Americans. J. Clin. Endocrinol. Metab 100 (2015), 3356–3363.
23. [23] Arnaud, J., Constans, J., Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). Hum. Genet 92 (1993), 183–188.
24. [24] Lauridsen, A.L., Vestergaard, P., Nexo, E., Mean serum concentration of vitamin D-binding protein (Gc globulin) is related to the Gc phenotype in women. Clin. Chem 47 (2001), 753–756.
25. [25] Hoofnagle, A.N., Eckfeldt, J.H., Lutsey, P.L., Vitamin D-binding protein concentrations quantified by mass spectrometry. N. Engl. J. Med 373 (2015), 1480–1482.
26. [26] Henderson, C.M., Lutsey, P.L., Misialek, J.R., Laha, T.J., Selvin, E., Eckfeldt, J.H., et al. Measurement by a novel LC-MS/MS methodology reveals similar serum concentrations of vitamin d-binding protein in blacks and whites. Clin. Chem 62 (2016), 179–187.
27. [27] Berg, A.H., Powe, C.E., Evans, M.K., Wenger, J., Ortiz, G., Zonderman, A.B., et al. 24,25-dihydroxyvitamin D3 and vitamin D status of community-dwelling black and white Americans. Clin. Chem 61 (2015), 877–884.
28. [28] Janssen, M.J., Wielders, J.P., Bekker, C.C., Boesten, L.S., Buijs, M.M., Heijboer, A.C., et al. Multicenter comparison study of current methods to measure 25-hydroxyvitamin D in serum. Steroids 77 (2012), 1366–1372.
29. [29] Carter, G.D., Accuracy of 25-hydroxyvitamin D assays: confronting the issues. Curr. Drug Targets 12 (2011), 19–28.
30. [30] Farrell, C.J., Martin, S., McWhinney, B., Straub, I., Williams, P., Herrmann, M., State-of-the-Art vitamin D assays: a comparison of automated immunoassays with liquid chromatography-tandem mass spectrometry methods. Clin. Chem 58 (2012), 531–542.
31. [31] Roth, H.J., Schmidt-Gayk, H., Weber, H., Niederau, C., Accuracy and clinical implications of seven 25-hydroxyvitamin D methods compared with liquid chromatography-tandem mass spectrometry as a reference. Ann. Clin. Biochem 45 (2008), 153–159.
32. [32] Looker, A.C., Pfeiffer, C.M., Lacher, D.A., Schleicher, R.L., Picciano, M.F., Yetley, E.A., Serum 25-hydroxyvitamin D status of the US population: 1988–1994 compared with 2000–2004. Am. J. Clin. Nutr 88 (2008), 1519–1527.
33. [33] Binkley, N., Krueger, D., Cowgill, C.S., Plum, L., Lake, E., Hansen, K.E., et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J. Clin. Endocrinol. Metab 89 (2004), 3152–3157.
34. [34] Binkley, N., Sempos, C.T., Vitamin D Standardization Program (VDSP), Standardizing vitamin D assays: the way forward. J. Bone Miner. Res 29 (2014), 1709–1714.
35. [35] Cashman, K.D., Dowling, K.G., Škrabáková, Z., Kiely, M., Lamberg-Allardt, C., Durazo-Arvizu, R.A., et al. Standardizing serum 25-hydroxyvitamin D data from four Nordic population samples using the Vitamin D Standardization Program protocols: shedding new light on vitamin D status in Nordic individuals. Scand. J. Clin. Lab. Invest 75 (2015), 549–561.
36. [36] Sarafin, K., Durazo-Arvizu, R., Tian, L., Phinney, K.W., Tai, S., Camara, J.E., et al. Standardizing 25-hydroxyvitamin D values from the Canadian Health Measures Survey. Am. J. Clin. Nutr 102 (2015), 1044–1050.
37. [37] van den Ouweland, J.M., Vogeser, M., Bächer, S., Vitamin D and metabolites measurement by tandem mass spectrometry. Rev. Endocr. Metab. Disord 14 (2013), 159–184.
38. [38] El-Khoury, J.M., Reineks, E.Z., Wang, S., Progress of liquid chromatography-mass spectrometry in measurement of vitamin D metabolites and analogues. Clin. Biochem 44 (2011), 66–76.
39. [39] Gathungu, R.M., Flarakos, C.C., Reddy, G.S., Vouros, P., The role of mass spectrometry in the analysis of vitamin D compounds. Mass Spectrom. Rev 32 (2013), 72–86.
40. [40] Higashi, T., Shimada, K., Toyo'oka, T., Advances in determination of vitamin D related compounds in biological samples using liquid chromatography-mass spectrometry: a review. J. Chromatogr. B. Analyt Technol Biomed Life Sci 878 (2010), 1654–1661.
41. [41] Volmer, D.A., Mendes, L.R., Stokes, C.S., Analysis of vitamin D metabolic markers by mass spectrometry: current techniques, limitations of the “gold standard” method, and anticipated future directions. Mass Spectrom. Rev 34 (2015), 2–23.
42. [42] Jones, G., Strugnell, S.A., DeLuca, H.F., Current understanding of the molecular actions of vitamin D. Physiol. Rev 78 (1998), 1193–1231.
43. [43] Di Rosa, M., Malaguarnera, M., Nicoletti, F., Malaguarnera, L., Vitamin D3: a helpful immuno-modulator. Immunology 134 (2011), 123–139.
44. [44] Jones, G., Metabolism and biomarkers of Vitamin D. Scand. J. Clin. Lab. Invest 72 (2012), 7–13.
45. [45] Kamao, M., Tatematsu, S., Hatakeyama, S., Sakaki, T., Sawada, N., Inouye, K., et al. C-3 epimerization of vitamin D3 metabolites and further metabolism of C-3 epimers: 25-hydroxyvitamin D3 is metabolized to 3-epi-25-hydroxyvitamin D3 and subsequently metabolized through C-1alpha or C-24 hydroxylation. J. Biol. Chem 279 (2004), 15897–15907.
46. [46] Saleh, L., Mueller, D., von Eckardstein, A., Analytical and clinical performance of the new Fujirebio 25-OH vitamin D assay, a comparison with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and three other automated assays. Clin. Chem. Lab. Med, 2015, 10.1515/cclm-2015-0427.
47. [47] Cavalier, E., Lukas, P., Bekaert, A.C., Peeters, S., Le Goff, C., Yayo, E., et al. Analytical and clinical evaluation of the new Fujirebio Lumipulse G non-competitive assay for 25(OH)-vitamin D and three immunoassays for 25(OH)D in healthy subjects, osteoporotic patients, third trimester pregnant women, healthy African subjects, hemodialyzed and intensive care patients. Clin. Chem. Lab. Med, 2015, 10.1515/cclm-2015-0923.
48. [48] Yu, S., Cheng, X., Fang, H., Zhang, R., Han, J., Qin, X., et al. 25OHD analogues and vacuum blood collection tubes dramatically affect the accuracy of automated immunoassays. Sci. Rep, 5, 2015, 14636.
49. [49] Cavalier, E., Lukas, P., Crine, Y., Peeters, S., Carlisi, A., Le Goff, C., et al. Evaluation of automated immunoassays for 25(OH)-vitamin determination in different critical populations before and after standardization of the assays. Clin. Chim. Acta 431 (2014), 60–65.
50. [50] Heijboer, A.C., Blankenstein, M.A., Kema, I.P., Buijs, M.M., Accuracy of 6 routine 25-hydroxyvitamin D assays: influence of vitamin D binding protein concentration. Clin. Chem 58 (2012), 543–548.
51. [51] Depreter, B., Heijboer, A.C., Langlois, M.R., Accuracy of three automated 25-hydroxyvitamin D assays in hemodialysis patients. Clin. Chim. Acta 415 (2013), 255–260.
52. [52] Bosworth, C.R., Levin, G., Robinson-Cohen, C., Hoofnagle, A.N., Ruzinski, J., Young, B., et al. The serum 24,25-dihydroxyvitamin D concentration, a marker of vitamin D catabolism, is reduced in chronic kidney disease. Kidney Int 82 (2012), 693–700.
53. [53] de Boer, I.H., Sachs, M.C., Chonchol, M., Himmelfarb, J., Hoofnagle, A.N., Ix, J.H., et al. Estimated GFR and circulating 24,25-dihydroxyvitamin D3 concentration: a participant-level analysis of 5 cohort studies and clinical trials. Am. J. Kidney Dis 64 (2014), 187–197.
54. [54] Seiden-Long, I., Vieth, R., Evaluation of a 1,25-dihydroxyvitamin D enzyme immunoassay. Clin. Chem 53 (2007), 1104–1108.
55. [55] Hawkes, C.P., Schnellbacher, S., Singh, R.J., Levine, M.A., 25-Hydroxyvitamin D can interfere with a common assay for 1,25-dihydroxyvitamin D in vitamin D intoxication. J. Clin. Endocrinol. Metab 100 (2015), 2883–2889.
56. [56] Ketha, H., Wadams, H., Lteif, A., Singh, R.J., Iatrogenic vitamin D toxicity in an infant–a case report and review of literature. J. Steroid Biochem. Mol. Biol 148 (2015), 14–18.
57. [57] Araki, T., Holick, M.F., Alfonso, B.D., Charlap, E., Romero, C.M., Rizk, D., et al. Vitamin D intoxication with severe hypercalcemia due to manufacturing and labeling errors of two dietary supplements made in the United States. J. Clin. Endocrinol. Metab 96 (2011), 3603–3608.
58. [58] van Helden, J., Weiskirchen, R., Experience with the first fully automated chemiluminescence immunoassay for the quantification of 1alpha, 25-dihydroxy-vitamin D. Clin. Chem. Lab. Med 53 (2015), 761–770.
59. [59] Valcour, A., Zierold, C., Podgorski, A.L., Olson, G.T., Wall, J.V., DeLuca, H.F., et al. A novel, fully-automated, chemiluminescent assay for the detection of 1,25-dihydroxyvitamin D in biological samples. J. Steroid Biochem. Mol. Biol, 2015, 10.1016/j.jsbmb.2015.08.005.
60. [60] Hussein, H., Ibrahim, F., Boudou, P., Evaluation of a new automated assay for the measurement of circulating 1,25-dihydroxyvitamin D levels in daily practice. Clin. Biochem 48 (2015), 1160–1162.
61. [61] Miller, N., Gruson, D., Implementation of automated testing for 1,25-dihydroxyvitamin D: return of experience from a core-laboratory. Clin. Biochem 49 (2015), 298–301.
62. [62] Denimal, D., Lemaire-Ewing, S., Duvillard, L., Performance of a new 1,25-dihydroxyvitamin D fully automated assay on IDS-iSYS system. Clin. Biochem 48 (2015), 1209–1210.
63. [63] Souberbielle, J.C., Cavalier, E., Delanaye, P., Massart, C., Brailly-Tabard, S., Cormier, C., et al. Serum calcitriol concentrations measured with a new direct automated assay in a large population of adult healthy subjects and in various clinical situations. Clin. Chim. Acta 451 (2015), 149–153.
64. [64] Vogeser, M., Seger, C., Pitfalls associated with the use of liquid chromatography-tandem mass spectrometry in the clinical laboratory. Clin. Chem 56 (2010), 1234–1244.
65. [65] Bouillon, R., Okamura, W.H., Norman, A.W., Structure-function relationships in the vitamin D endocrine system. Endocr. Rev 16 (1995), 200–257.
66. [66] Brown, A.J., Slatopolsky, E., Vitamin D analogs: therapeutic applications and mechanisms for selectivity. Mol. Aspects Med 29 (2008), 433–452.
67. [67] Netzel, B.C., Cradic, K.W., Bro, E.T., Girtman, A.B., Cyr, R.C., Singh, R.J., et al. Increasing liquid chromatography-tandem mass spectrometry throughput by mass tagging: a sample-multiplexed high-throughput assay for 25-hydroxyvitamin D2 and D3. Clin. Chem 57 (2011), 431–440.
68. [68] Aronov, P.A., Hall, L.M., Dettmer, K., Stephensen, C.B., Hammock, B.D., Metabolic profiling of major vitamin d metabolites using diels-alder derivatization and ultra-performance liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem 391 (2008), 1917–1930.
69. [69] Eyles, D., Anderson, C., Ko, P., Jones, A., Thomas, A., Burne, T., et al. A sensitive LC/MS/MS assay of 25OH vitamin D3 and 25OH vitamin D2 in dried blood spots. Clin. Chim. Acta 403 (2009), 145–151.
70. [70] Duan, X., Weinstock-Guttman, B., Wang, H., Bang, E., Li, J., Ramanathan, M., et al. Ultrasensitive quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry. Anal. Chem 82 (2010), 2488–2497.
71. [71] Wang, Z., Senn, T., Kalhorn, T., Zheng, X.E., Zheng, S., Davis, C.L., et al. Simultaneous measurement of plasma vitamin D(3) metabolites, including 4beta,25-dihydroxyvitamin D(3), using liquid chromatography-tandem mass spectrometry. Anal. Biochem 418 (2011), 126–133.
72. [72] Ding, S., Schoenmakers, I., Jones, K., Koulman, A., Prentice, A., Volmer, D.A., Quantitative determination of vitamin D metabolites in plasma using uhplc-ms/ms. Anal. Bioanal. Chem 398 (2010), 779–789.
73. [73] Strathmann, F.G., Laha, T.J., Hoofnagle, A.N., Quantification of 1alpha,25-dihydroxy vitamin D by immunoextraction and liquid chromatography-tandem mass spectrometry. Clin. Chem 57 (2011), 1279–1285.
74. [74] Ogawa, S., Ooki, S., Morohashi, M., Yamagata, K., Higashi, T., A novel Cookson-type reagent for enhancing sensitivity and specificity in assessment of infant vitamin D status using liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom 27 (2013), 2453–2460.
75. [75] Ogawa, S., Ooki, S., Shinoda, K., Higashi, T., Analysis of urinary vitamin D3 metabolites by liquid chromatography/tandem mass spectrometry with ESI-enhancing and stable isotope-coded derivatization. Anal. Bioanal. Chem 406 (2014), 6647–6654.
76. 3 in neonatal blood samples. Biomed. Chromatogr, 2015, 10.1002/bmc.3633.
77. [77] Hedman, C.J., Wiebe, D.A., Dey, S., Plath, J., Kemnitz, J.W., Ziegler, T.E., Development of a sensitive LC/MS/MS method for vitamin D metabolites: 1,25 Dihydroxyvitamin D2 & 3 measurement using a novel derivatization agent. J. Chromatogr. B. Analyt Technol Biomed Life Sci 953–954 (2014), 62–67.
78. [78] Müller, M.J., Volmer, D.A., Mass spectrometric profiling of vitamin D metabolites beyond 25-hydroxyvitamin D. Clin. Chem 61 (2015), 1033–1048.
79. [79] Geib, T., Meier, F., Schorr, P., Lammert, F., Stokes, C.S., Volmer, D.A., A simple micro-extraction plate assay for automated LC-MS/MS analysis of human serum 25-hydroxyvitamin D levels. J. Mass Spectrom 50 (2015), 275–279.
80. [80] Baecher, S., Geyer, R., Lehmann, C., Vogeser, M., Absorptive chemistry based extraction for LC-MS/MS analysis of small molecule analytes from biological fluids – an application for 25-hydroxyvitamin D. Clin. Chem. Lab. Med 52 (2014), 363–371.
81. [81] Musteata, M.L., Musteata, F.M., Overview of extraction methods for analysis of vitamin D and its metabolites in biological samples. Bioanalysis 3 (2011), 1987–2002.
82. [82] Sauter, G., Berr, F., Beuers, U., Fischer, S., Paumgartner, G., Serum concentrations of 7alpha-hydroxy-4-cholesten-3-one reflect bile acid synthesis in humans. Hepatology 24 (1996), 123–126.
83. [83] Shah, I., James, R., Barker, J., Petroczi, A., Naughton, D.P., Misleading measures in vitamin D analysis: a novel LC-MS/MS assay to account for epimers and isobars. Nutr. J., 10, 2011, 46.
84. [84] Maunsell, Z., Wright, D.J., Rainbow, S.J., Routine isotope-dilution liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of the 25-hydroxy metabolites of vitamins D2 and D3. Clin. Chem 51 (2005), 1683–1690.
85. [85] Singh, R.J., Taylor, R.L., Reddy, G.S., Grebe, S.K., C-3 epimers can account for a significant proportion of total circulating 25-hydroxyvitamin D in infants, complicating accurate measurement and interpretation of vitamin D status. J. Clin. Endocrinol. Metab 91 (2006), 3055–3061.
86. [86] van den Ouweland, J.M., Beijers, A.M., van Daal, H., Overestimation of 25-hydroxyvitamin D3 by increased ionisation efficiency of 3-epi-25-hydroxyvitamin D3 in LC-MS/MS methods not separating both metabolites as determined by an LC-MS/MS method for separate quantification of 25-hydroxyvitamin D3, 3-epi-25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 in human serum. J. Chromatogr. B. Analyt Technol Biomed Life Sci 967 (2014), 195–202.
87. [87] Bunch, D.R., Miller, A.Y., Wang, S., Development and validation of a liquid chromatography-tandem mass spectrometry assay for serum 25-hydroxyvitamin D2/D3 using a turbulent flow online extraction technology. Clin. Chem. Lab. Med 47 (2009), 1565–1572.
88. [88] Thibeault, D., Caron, N., Djiana, R., Kremer, R., Blank, D., Development and optimization of simplified LC-MS/MS quantification of 25-hydroxyvitamin D using protein precipitation combined with on-line solid phase extraction (SPE). J. Chromatogr. B 883–884 (2012), 120–127.
89. [89] Kushnir, M.M., Ray, J.A., Rockwood, A.L., Roberts, W.L., La'ulu, S.L., Whittington, J.E., et al. Rapid analysis of 25-hydroxyvitamin D2 and D3 by liquid chromatography-tandem mass spectrometry and association of vitamin D and parathyroid hormone concentrations in healthy adults. Am. J. Clin. Pathol 134 (2010), 148–156.
90. [90] Herrmann, M., Harwood, T., Gaston-Parry, O., Kouzios, D., Wong, T., Lih, A., et al. A new quantitative LC tandem mass spectrometry assay for serum 25-hydroxy vitamin D. Steroids 75 (2010), 1106–1112.
91. [91] Bruce, S.J., Rochat, B., Béguin, A., Pesse, B., Guessous, I., Boulat, O., et al. Analysis and quantification of vitamin D metabolites in serum by ultra-performance liquid chromatography coupled to tandem mass spectrometry and high-resolution mass spectrometry-a method comparison and validation. Rapid Commun. Mass Spectrom 27 (2013), 200–206.
92. [92] Liebisch, G., Matysik, S., Accurate and reliable quantification of 25-hydroxy-vitamin D species by liquid chromatography high-resolution tandem mass spectrometry. J. Lipid Res 56 (2015), 1234–1239.
93. [93] Yuan, C., Kosewick, J., He, X., Kozak, M., Wang, S., Sensitive measurement of serum 1α,25 dihydroxyvitamin d by liquid chromatography/tandem mass spectrometry after removing interference with immunoaffinity extraction. Rapid Commun. Mass Spectrom 25 (2011), 1241–1249.
94. [94] Chen, H., McCoy, L.F., Schleicher, R.L., Pfeiffer, C.M., Measurement of 25-hydroxyvitamin D3 (25OHD3) and 25-hydroxyvitamin D2 (25OHD2) in human serum using liquid chromatography-tandem mass spectrometry and its comparison to a radioimmunoassay method. Clin. Chim. Acta 391 (2008), 6–12.
95. [95] van den Ouweland, J.M., Beijers, A.M., Demacker, P.N., van Daal, H., Measurement of 25-OH-vitamin D in human serum using liquid chromatography tandem-mass spectrometry with comparison to radioimmunoassay and automated immunoassay. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci 878 (2010), 1163–1168.
96. [96] Saenger, A.K., Laha, T.J., Bremner, D.E., Sadrzadeh, S.M., Quantification of serum 25-hydroxyvitamin D(2) and D(3) using HPLC-tandem mass spectrometry and examination of reference intervals for diagnosis of vitamin D deficiency. Am. J. Clin. Pathol 125 (2006), 914–920.
97. [97] Bedner, M., Lippa, K.A., 25-Hydroxyvitamin D isomerizes to pre-25-hydroxyvitamin D in solution: considerations for calibration in clinical measurements. Anal. Bioanal. Chem 407 (2015), 8079–8086.
98. [98] Huang, M., Cadwallader, A.B., Heltsley, R., Mechanism of error caused by isotope-labeled internal standard: accurate method for simultaneous measurement of vitamin D and pre-vitamin D by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom 28 (2014), 2101–2110.
99. [99] Couchman, L., Benton, C.M., Moniz, C.F., Variability in the analysis of 25-hydroxyvitamin D by liquid chromatography-tandem mass spectrometry: the devil is in the detail. Clin. Chim. Acta 413 (2012), 1239–1243.
100. [100] Baecher, S., Leinenbach, A., Wright, J.A., Pongratz, S., Kobold, U., Thiele, R., Simultaneous quantification of four vitamin D metabolites in human serum using high performance liquid chromatography tandem mass spectrometry for vitamin D profiling. Clin. Biochem 45 (2012), 1491–1496.
101. [101] Bogusz, M.J., Al Enazi, E., Tahtamoni, M., Jawaad, J.A., Al Tufail, M., Determination of serum vitamins 25-OH-D2 and 25-OH-D3 with liquid chromatography-tandem mass spectrometry using atmospheric pressure chemical ionization or electrospray source and core-shell or sub-2 mum particle columns: a comparative study. Clin. Biochem 44 (2011), 1329–1337.
102. [102] Elder, P.A., Lewis, J.G., King, R.I., Florkowski, C.M., An anomalous result from gel tubes for vitamin D. Clin. Chim. Acta, 410, 2009, 95.
103. [103] Qi, Y., Geib, T., Schorr, P., Meier, F., Volmer, D.A., On the isobaric space of 25-hydroxyvitamin D in human serum: potential for interferences in liquid chromatography/tandem mass spectrometry, systematic errors and accuracy issues. Rapid Commun. Mass Spectrom 29 (2015), 1–9.
104. [104] Stepman, H.C., Vanderroost, A., Van Uytfanghe, K., Thienpont, L.M., Candidate reference measurement procedures for serum 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 by using isotope-dilution liquid chromatography-tandem mass spectrometry. Clin. Chem 57 (2011), 441–448.
105. [105] Tai, S.S., Bedner, M., Phinney, K.W., Development of a candidate reference measurement procedure for the determination of 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 in human serum using isotope-dilution liquid chromatography-tandem mass spectrometry. Anal. Chem 82 (2010), 1942–1948.
106. [106] Mineva, E.M., Schleicher, R.L., Chaudhary-Webb, M., Maw, K.L., Botelho, J.C., Vesper, H.W., et al. A candidate reference measurement procedure for quantifying serum concentrations of 25-hydroxyvitamin D3 and 25-hydroxyvitamin D2 using isotope-dilution liquid chromatography-tandem mass spectrometry. Anal. Bioanal. Chem 407 (2015), 5615–5624.
107. [107] Stöckl, D., Sluss, P.M., Thienpont, L.M., Specifications for trueness and precision of a reference measurement system for serum/plasma 25-hydroxyvitamin D analysis. Clin. Chim. Acta 408 (2009), 8–13.
108. [108] Tai, S.S., Nelson, M.A., Candidate reference measurement procedure for the determination of (24R),25-dihydroxyvitamin D3 in human serum using isotope-dilution liquid chromatography-tandem mass spectrometry. Anal. Chem 87 (2015), 7964–7970.
109. [109] Yates, A.M., Bowron, A., Calton, L., Heynes, J., Field, H., Rainbow, S., et al. Interlaboratory variation in 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 is significantly improved if common calibration material is used. Clin. Chem 54 (2008), 2082–2084.
110. [110] Carter, G.D., Jones, J.C., Use of a common standard improves the performance of liquid chromatography-tandem mass spectrometry methods for serum 25-hydroxyvitamin-D. Ann. Clin. Biochem 46 (2009), 79–81.
111. [111] Bedner, M., Lippa, K.A., Tai, S.S., An assessment of 25-hydroxyvitamin D measurements in comparability studies conducted by the Vitamin D Metabolites Quality Assurance Program. Clin. Chim. Acta 426 (2013), 6–11.
112. [112] van den Ouweland, J.M., Beijers, A.M., van Daal, H., Fast separation of 25-hydroxyvitamin D3 from 3-epi-25-hydroxyvitamin D3 in human serum by liquid chromatography–tandem mass spectrometry: variable prevalence of 3-epi-25-hydroxyvitamin D3 in infants, children, and adults. Clin. Chem 57 (2011), 1618–1619.
113. [113] Bailey, D., Veljkovic, K., Yazdanpanah, M., Adeli, K., Analytical measurement and clinical relevance of vitamin D3 C3-epimer. Clin. Biochem 46 (2013), 190–196.
114. [114] Heath, A.K., Williamson, E.J., Ebeling, P.R., Kvaskoff, D., Eyles, D.W., English, D.R., Measurements of 25-hydroxyvitamin D concentrations in archived dried blood spots are reliable and accurately reflect those in plasma. J. Clin. Endocrinol. Metab 99 (2014), 3319–3324.
115. [115] Larkin, E.K., Gebretsadik, T., Koestner, N., Newman, M.S., Liu, Z., Carroll, K.N., et al. Agreement of blood spot card measurements of vitamin D levels with serum, whole blood specimen types and a dietary recall instrument. PLoS ONE, 6, 2011, e16602.
116. [116] Hoeller, U., Baur, M., Roos, F.F., Brennan, L., Daniel, H., Fallaize, R., et al. Application of dried blood spots to determine vitamin D status in a large nutritional study with unsupervised sampling: the Food4Me project. Br. J. Nutr 115 (2016), 202–211.
117. [117] Newman, M.S., Brandon, T.R., Groves, M.N., Gregory, W.L., Kapur, S., Zava, D.T., A liquid chromatography/tandem mass spectrometry method for determination of 25-hydroxy vitamin D2 and 25-hydroxy vitamin D3 in dried blood spots: a potential adjunct to diabetes and cardiometabolic risk screening. J. Diabetes Sci. Technol 3 (2009), 156–162.
118. [118] Higashi, T., Suzuki, M., Hanai, J., Inagaki, S., Min, J.Z., Shimada, K., et al. A specific LC/ESI-MS/MS method for determination of 25-hydroxyvitamin D3 in neonatal dried blood spots containing a potential interfering metabolite, 3-epi-25-hydroxyvitamin D3. J. Sep. Sci 34 (2011), 725–732.
119. [119] Higashi, T., Shibayama, Y., Fuji, M., Shimada, K., Liquid chromatography-tandem mass spectrometric method for the determination of salivary 25-hydroxyvitamin D3: a noninvasive tool for the assessment of vitamin D status. Anal. Bioanal. Chem 391 (2008), 229–238.
120. [120] Holmøy, T., Moen, S.M., Gundersen, T.A., Holick, M.F., Fainardi, E., Castellazzi, M., et al. 25-hydroxyvitamin D in cerebrospinal fluid during relapse and remission of multiple sclerosis. Mult. Scler 15 (2009), 1280–1285.
121. [121] Gröschl, M., Current status of salivary hormone analysis. Clin. Chem 54 (2008), 1759–1769.
122. [122] Fairney, A., Saphier, P.W., Studies on the measurement of 25-hydroxy vitamin D in human saliva. Br. J. Nutr 57 (1987), 13–25.
123. [123] Higashi, T., Goto, A., Morohashi, M., Ogawa, S., Komatsu, K., Sugiura, T., et al. Development and validation of a method for determination of plasma 25-hydroxyvitamin D3 3-sulfate using liquid chromatography/tandem mass spectrometry. J. Chromatogr. B. Analyt Technol Biomed Life Sci 969 (2014), 230–234.
124. [124] Nagubandi, S., Londowski, J.M., Bollman, S., Tietz, P., Kumar, R., Synthesis and biological activity of vitamin D3 3 beta-sulfate. Role of vitamin D3 sulfates in calcium homeostasis. J. Biol. Chem 256 (1981), 5536–5539.
125. [125] Hollis, B.W., Assessment and interpretation of circulating 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in the clinical environment. Rheum. Dis. Clin. North Am 38 (2012), 29–44.
126. [126] Quarles, L.D., Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat. Rev. Endocrinol 8 (2012), 276–286.
127. [127] Kissmeyer, A.M., Sonne, K., Sensitive analysis of 1α,25-dihydroxyvitamin D3 in biological fluids by liquid chromatography-tandem mass spectrometry. J. Chromatogr. A 935 (2001), 93–103.
128. [128] Casetta, B., Jans, I., Billen, J., Vanderschueren, D., Bouillon, R., Development of a method for the quantification of 1alpha,25(OH)2-vitamin D3 in serum by liquid chromatography tandem mass spectrometry without derivatization. Eur. J. Mass Spectrom. (Chichester, Eng.) 16 (2010), 81–89.
129. [129] Mahlow, J., Bunch, D.R., Wang, S., Quantification of 1,25-dihydroxyvitamin D2 and D3 in serum using liquid chromatography-tandem mass spectrometry. Methods Mol. Biol 1378 (2016), 291–300.
130. [130] Chan, N., Kaleta, E.J., Quantitation of 1α,25-dihydroxyvitamin D by LC-MS/MS using solid-phase extraction and fixed-charge derivitization in comparison to immunoextraction. Clin. Chem. Lab. Med 53 (2015), 1399–1407.
131. [131] Mena-Bravo, A., Ferreiro-Vera, C., Priego-Capote, F., Maestro, M.A., Mouriño, A., Quesada-Gómez, J.M., et al. Quantitative analytical method to evaluate the metabolism of vitamin D. Clin. Chim. Acta 442 (2015), 6–12.
132. [132] Shah, I., Petroczi, A., Naughton, D.P., Method for simultaneous analysis of eight analogues of vitamin D using liquid chromatography tandem mass spectrometry. Chem. Cent. J., 6, 2012, 112.
133. [133] van Ballegooijen, A.J., Gansevoort, R.T., Lambers-Heerspink, H.J., de Zeeuw, D., Visser, M., Brouwer, I.A., et al. Plasma 1,25-dihydroxyvitamin D and the risk of developing hypertension: the prevention of renal and vascular end-stage disease study. Hypertension 66 (2015), 563–570.
134. [134] Rebholz, C.M., Grams, M.E., Lutsey, P.L., Hoofnagle, A.N., Misialek, J.R., Inker, L.A., et al. Chronic kidney disease biomarkers consortium, biomarkers of vitamin D status and risk of ESRD. Am. J. Kidney Dis 67 (2016), 235–242.
135. [135] Reddy, G.S., Muralidharan, K.R., Okamura, W.H., Tserng, K.Y., McLane, J.A., Metabolism of 1alpha,25-dihydroxyvitamin D(3) and its C-3 epimer 1alpha,25-dihydroxy-3-epi-vitamin D(3) in neonatal human keratinocytes. Steroids 66 (2001), 441–450.
136. [136] Kamao, M., Hatakeyama, S., Sakaki, T., Sawada, N., Inouye, K., Kubodera, N., et al. Measurement and characterization of C-3 epimerization activity toward vitamin D3. Arch. Biochem. Biophys 436 (2005), 196–205.
137. [137] Norman, A.W., Bouillon, R., Farach-Carson, M.C., Bishop, J.E., Zhou, L.X., Nemere, I., et al. Demonstration that 1 beta,25-dihydroxyvitamin D3 is an antagonist of the nongenomic but not genomic biological responses and biological profile of the three A-ring diastereomers of 1 alpha,25-dihydroxyvitamin D3. J. Biol. Chem 268 (1993), 20022–20030.
138. [138] Brown, A.J., Ritter, C., Slatopolsky, E., Muralidharan, K.R., Okamura, W.H., Reddy, G.S., 1Alpha,25-dihydroxy-3-epi-vitamin D3, a natural metabolite of 1alpha,25-dihydroxyvitamin D3, is a potent suppressor of parathyroid hormone secretion. J. Cell. Biochem 73 (1999), 106–113.
139. [139] Harant, H., Spinner, D., Reddy, G.S., Lindley, I.J., Natural metabolites of 1alpha,25-dihydroxyvitamin D(3) retain biologic activity mediated through the vitamin D receptor. J. Cell. Biochem 78 (2000), 112–120.
140. [140] Fleet, J.C., Bradley, J., Reddy, G.S., Ray, R., Wood, R.J., 1 alpha,25-(OH)2-vitamin D3 analogs with minimal in vivo calcemic activity can stimulate significant transepithelial calcium transport and mRNA expression in vitro. Arch. Biochem. Biophys 329 (1996), 228–234.
141. [141] Flynn, N., Lam, F., Dawnay, A., Enhanced 3-epi-25-hydroxyvitamin D3 signal leads to overestimation of its concentration and amplifies interference in 25-hydroxyvitamin D LC-MS/MS assays. Ann. Clin. Biochem 51 (2014), 352–359.
142. [142] Lensmeyer, G., Poquette, M., Wiebe, D., Binkley, N., The C3-epimer of 25-hydroxyvitamin D3 is present in adult serum. J. Clin. Endocrinol. Metab 97 (2012), 163–168.
143. [143] Keevil, B., Does the presence of 3-epi-25OHD3 affect the routine measurement of vitamin D using liquid chromatography tandem mass spectrometry?. Clin. Chem. Lab. Med 50 (2011), 181–183.
144. [144] Schleicher, R.L., Encisco, S.E., Chaudhary-Webb, M., Paliakov, E., McCoy, L.F., Pfeiffer, C.M., Isotope dilution ultra performance liquid chromatography-tandem mass spectrometry method for simultaneous measurement of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3 and 3-epi-25-hydroxyvitamin D3 in human serum. Clin. Chim. Acta 412 (2011), 1594–1599.
145. [145] Cashman, K.D., Kinsella, M., Walton, J., Flynn, A., Hayes, A., Lucey, A.J., et al. The 3 epimer of 25-hydroxycholecalciferol is present in the circulation of the majority of adults in a nationally representative sample and has endogenous origins. J. Nutr 144 (2014), 1050–1057.
146. [146] Teegarden, M.D., Riedl, K.M., Schwartz, S.J., Chromatographic separation of PTAD-derivatized 25-hydroxyvitamin D3 and its C-3 epimer from human serum and murine skin. J. Chromatogr. B. Analyt Technol Biomed Life Sci 991 (2015), 118–121.
147. [147] Kaufmann, M., Gallagher, J.C., Peacock, M., Schlingmann, K.P., Konrad, M., DeLuca, H.F., et al. Clinical utility of simultaneous quantitation of 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D by LC-MS/MS involving derivatization with DMEQ-TAD. J. Clin. Endocrinol. Metab 99 (2014), 2567–2574.
148. [148] C.D. Chouinard, C.R. Beekman, T.J. Garrett, R.A. Yost, Ion mobility strategies for separation of vitamin D metabolites by LC-MS/MS. Presented at: Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy (PITTCON) 2015 Conference and Expo, 2015 Mar 8–12, New Orleans, LA.
149. [149] Abdel-Khalik, J., Crick, P.J., Carter, G.D., Makin, H.L., Wang, Y., Griffiths, W.J., Studies on the analysis of 25-hydroxyvitamin D3 by isotope-dilution liquid chromatography-tandem mass spectrometry using enzyme-assisted derivatisation. Biochem. Biophys. Res. Commun 446 (2014), 745–750.
150. [150] Bailey, D., Perumal, N., Yazdanpanah, M., Al Mahmud, A., Baqui, A.H., Adeli, K., et al. Maternal-fetal-infant dynamics of the C3-epimer of 25-hydroxyvitamin D. Clin. Biochem 47 (2014), 816–822.
151. [151] Yazdanpanah, M., Bailey, D., Walsh, W., Wan, B., Adeli, K., Analytical measurement of serum 25-OH-vitamin D3, 25-OH-vitamin D2 and their C3-epimers by LC-MS/MS in infant and pediatric specimens. Clin. Biochem 46 (2013), 1264–1271.
152. [152] Strathmann, F.G., Sadilkova, K., Laha, T.J., Lesourd, S.E., Bornhorst, J.A., Hoofnagle, A.N., et al. 3-epi-25 hydroxyvitamin D concentrations are not correlated with age in a cohort of infants and adults. Clin. Chim. Acta 413 (2012), 203–206.
153. [153] Granado-Lorencio, F., Muňoz Garcia-Heras, L., Blanco-Navarro, I., Pérez-Sacristán, B., Assessment of 3-epi-25-OH-D3 in preterm and full term infant samples and its relationship to demographic, anthropometric and biochemical determinants. Clin. Biochem 47 (2014), 853–856.
154. [154] Goldman, M.M., Viec, K.V., Caulfield, M.P., Reitz, R.E., McPhaul, M.J., Clarke, N.J., The measurement of 3-epimer 25-hydroxyvitamin D by mass spectrometry in clinical specimens detects inconsequential levels in adult subjects. J. Investig. Med 62 (2014), 690–695.
155. [155] Ooms, N., van Daal, H., Beijers, A.M., Gerrits, P., Semmekrot, B., van den Ouweland, J.M., Time-course analysis of 3-epi-25-hydroxyvitamin D3 shows markedly elevated levels in early life, particularly from vitamin D supplementation in preterm infants. Pediatr. Res, 2015, 10.1038/pr.2015.251.
156. [156] Hanson, C., Jones, G., Lyden, E., Kaufmann, M., Armas, L., Anderson-Berry, A., Vitamin D metabolism in the premature newborn: a randomized trial. Clin. Nutr, 2015, 10.1016/j.clnu.2015.07.023 pii: S0261-5614(15)00219-8.
157. [157] Hanson, C., Anderson-Berry, A., Lyden, E., Kaufmann, M., Wu, A., Elliott, E., et al. Dynamics of Vitamin D Metabolism in maternal-fetal dyads. J. Pediatr. Gastroenterol. Nutr 62 (2016), 486–490.
158. [158] Hazell, T.J., Gallo, S., Berzina, I., Vanstone, C.A., Rodd, C., Weiler, H.A., Plasma 25-hydroxyvitamin D, more so than its epimer, has a linear relationship to leaner body composition across infancy in healthy term infants. Appl. Physiol. Nutr. Metab 39 (2014), 1137–1143.
159. [159] Gallo, S., Comeau, K., Vanstone, C., Agellon, S., Sharma, A., Jones, G., et al. Effect of different dosages of oral vitamin D supplementation on vitamin D status in healthy, breastfed infants: a randomized trial. JAMA 309 (2013), 1785–1792.
160. [160] Fatani, T., Binjab, A., Weiler, H., Sharma, A., Rodd, C., Persistent elevation of fibroblast growth factor 23 concentrations in healthy appropriate-for-gestational-age preterm infants. J. Pediatr. Endocrinol. Metab 28 (2015), 825–832.
161. [161] Chailurkit, L., Aekplakorn, W., Ongphiphadhanakul, B., Serum C3 epimer of 25-hydroxyvitamin D and its determinants in adults: a national health examination survey in Thais. Osteoporos. Int 26 (2015), 2339–2344.
162. [162] Lutsey, P.L., Eckfeldt, J.H., Ogagarue, E.R., Folsom, A.R., Michos, E.D., Gross, M., The 25-hydroxyvitamin D3 C-3 epimer: distribution, correlates, and reclassification of 25-hydroxyvitamin D status in the population-based Atherosclerosis Risk in Communities Study (ARIC). Clin. Chim. Acta 442 (2015), 75–81.
163. [163] Wright, M.J., Halsall, D.J., Keevil, B.G., Removal of 3-epi-25-hydroxyvitamin D3 interference by liquid chromatography-tandem mass spectrometry is not required for the measurement of 25-hydroxyvitamin D3 in patients older than 2 years. Clin. Chem 58 (2012), 1719–1720.
164. [164] Karras, S.N., Shah, I., Petroczi, A., Goulis, D.G., Bili, H., Papadopoulou, F., et al. An observational study reveals that neonatal vitamin D is primarily determined by maternal contributions: implications of a new assay on the roles of vitamin D forms. Nutr. J., 12, 2013, 77.
165. [165] Shah, I., Petroczi, A., Naughton, D.P., Exploring the role of vitamin D in type 1 diabetes, rheumatoid arthritis, and Alzheimer disease: new insights from accurate analysis of 10 forms. J. Clin. Endocrinol. Metab 99 (2014), 808–816.
166. [166] Wiebe, D., Binkley, N., Case report: three patients with substantial serum levels of 3-epi-25(OH)D including one with 3-epi-25(OH)D2 while on high-dose ergocalciferol. J. Clin. Endocrinol. Metab 99 (2014), 1117–1121.
167. [167] Sekimoto, H., Siu-Caldera, M.L., Weiskopf, A., Vouros, P., Muralidharan, K.R., Okamura, W.H., et al. 1alpha,25-dihydroxy-3-epi-vitamin D3: in vivo metabolite of 1alpha,25-dihydroxyvitamin D3 in rats. FEBS Lett 448 (1999), 278–282.
168. [168] Grant, C.C., Stewart, A.W., Scragg, R., Milne, T., Rowden, J., Ekeroma, A., et al. Vitamin D during pregnancy and infancy and infant serum 25-hydroxyvitamin D concentration. Pediatrics 133 (2014), e143–e153.
169. [169] Monangi, N., Slaughter, J.L., Dawodu, A., Smith, C., Akinbi, H.T., Vitamin D status of early preterm infants and the effects of vitamin D intake during hospital stay. Arch. Dis. Child. Fetal Neonatal Ed 99 (2014), F166–F168.
170. [170] Pinto, K., Collins, C.T., Gibson, R.A., Andersen, C.C., Vitamin D in preterm infants: a prospective observational study. J. Paediatr. Child Health 51 (2015), 679–681.
171. [171] Wagner, D., Hanwell, H.E., Schnabl, K., Yazdanpanah, M., Kimball, S., Fu, L., et al. The ratio of serum 24,25-dihydroxyvitamin D3 to 25-hydroxyvitamin D3 is predictive of 25 hydroxyvitamin D3 response to vitamin D3 supplementation. J. Steroid Biochem. Mol. Biol 126 (2011), 72–77.
172. [172] Edouard, T., Husseini, A., Glorieux, F.H., Rauch, F., Serum 24,25-dihydroxyvitamin D concentrations in osteogenesis imperfecta: relationship to bone parameters. J. Clin. Endocrinol. Metab 97 (2012), 1243–1249.
173. [173] Kobold, U., Approaches to measurement of vitamin D concentrations – mass spectrometry. Scand. J. Clin. Lab. Invest. Suppl 243 (2012), 54–59.
174. [174] Cashman, K.D., Hayes, A., Galvin, K., Merkel, J., Jones, G., Kaufmann, M., et al. Significance of serum 24,25-dihydroxyvitamin D in the assessment of vitamin D status: a double-edged sword?. Clin. Chem 61 (2015), 636–645.
175. [175] Reddy, G.S., Tserng, K.Y., Calcitroic acid, end product of renal metabolism of 1,25-dihydroxyvitamin D3 through C-24 oxidation pathway. Biochemistry 28 (1989), 1763–1769.
176. [176] St-Arnaud, R., Arabian, A., Travers, R., Barletta, F., Raval-Pandya, M., Chapin, K., et al. Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1, 25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 141 (2000), 2658–2666.
177. [177] Schlingmann, K.P., Kaufmann, M., Weber, S., Irwin, A., Goos, C., John, U., et al. Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N. Engl. J. Med 365 (2011), 410–421.
178. [178] Dauber, A., Nguyen, T.T., Sochett, E., Cole, D.E., Horst, R., Abrams, S.A., et al. Genetic defect in CYP24A1, the vitamin D 24-hydroxylase gene, in a patient with severe infantile hypercalcemia. J. Clin. Endocrinol. Metab 97 (2012), E268–E274.
179. [179] Norman, A.W., Henry, H.L., Malluche, H.H., 24R,25-Dihydroxyvitamin D3 and 1 alpha,25-dihydroxyvitamin D3 are both indispensable for calcium and phosphorus homeostasis. Life Sci 27 (1980), 229–237.
180. [180] St-Arnaud, R., Naja, R.P., Vitamin D metabolism, cartilage and bone fracture repair. Mol. Cell. Endocrinol 347 (2011), 48–54.
181. [181] Higashi, T., Awada, D., Shimada, K., Determination of 24,25-dihydroxyvitamin D3 in human plasma using liquid chromatography-mass spectrometry after derivatization with a Cookson-type reagent. Biomed. Chromatogr 15 (2001), 133–140.
182. [182] Tsugawa, N., Suhara, Y., Kamao, M., Okano, T., Determination of 25-hydroxyvitamin D in human plasma using high-performance liquid chromatography-tandem mass spectrometry. Anal. Chem 77 (2005), 3001–3007.
183. [183] Burild, A., Frandsen, H.L., Jakobsen, J., Simultaneous quantification of vitamin D3, 25-hydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 in human serum by LC-MS/MS. Scand. J. Clin. Lab. Invest 74 (2014), 418–423.
184. [184] Ketha, H., Kumar, R., Singh, R.J., LC-MS/MS for Identifying Patients with CYP24A1 Mutations. Clin. Chem 62 (2016), 236–242.
185. [185] Norman, A.W., Okamura, W.H., Bishop, J.E., Henry, H.L., Update on biological actions of 1alpha,25(OH)2-vitamin D3 (rapid effects) and 24R,25(OH)2-vitamin D3. Mol. Cell. Endocrinol 197 (2002), 1–13.
186. [186] Stubbs, J.R., Zhang, S., Friedman, P.A., Nolin, T.D., Decreased conversion of 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 following cholecalciferol therapy in patients with CKD. Clin. J. Am. Soc. Nephrol 9 (2014), 1965–1973.